ZNF582 overexpression restrains the progression of clear cell renal cell carcinoma by enhancing the binding of TJP2 and ERK2 and inhibiting ERK2 phosphorylation.

导出 OA

翻译打印收藏纠错

第一作者： Wuping,Yang

第一单位： Department of Urology, Peking University First Hospital, Beijing, 100034, P.R. China.

作者： Wuping,Yang ^[1] ; Zedan,Zhang ^[2] ; Lei,Li ^[3] ; Kenan,Zhang ^[1] ; Yawei,Xu ^[2] ; Mancheng,Xia ^[3] ; Jingcheng,Zhou ^[1] ; Yanqing,Gong ^[2] ; Jinchao,Chen ^[3] ; Kan,Gong ^[1]

作者单位： Department of Urology, Peking University First Hospital, Beijing, 100034, P.R. China. ^[1] Hereditary Kidney Cancer Research Center, Peking University First Hospital, Beijing, 100034, P.R. China. ^[2] Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Beijing, P.R. China. ^[3] Department of Urology, Peking University First Hospital, Beijing, 100034, P.R. China. yqgong@bjmu.edu.cn. ^[4] Hereditary Kidney Cancer Research Center, Peking University First Hospital, Beijing, 100034, P.R. China. yqgong@bjmu.edu.cn. ^[5] Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Beijing, P.R. China. yqgong@bjmu.edu.cn. ^[6] Department of Urologic Surgery, The Cancer Hospital of the University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, 310022, P.R. China. runner421@126.com. ^[7] Department of Urology, Peking University First Hospital, Beijing, 100034, P.R. China. gongkan_pku@126.com. ^[8] Hereditary Kidney Cancer Research Center, Peking University First Hospital, Beijing, 100034, P.R. China. gongkan_pku@126.com. ^[9] Beijing Key Laboratory of Urogenital Diseases (Male) Molecular Diagnosis and Treatment Center, Beijing, P.R. China. gongkan_pku@126.com. ^[10]